Drug Trial News

RSS

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug, which is being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

31 Mar 2020

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.

From AstraZeneca 30 Mar 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Investigational drug vericiguat benefits patients with worsening heart failure

Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Taking ticagrelor alone better for patients with complex heart disease

Patients with complex heart disease who stopped taking aspirin three months after the insertion of one or more coronary stents and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor over the same period.

30 Mar 2020

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Experimental drug could offer new treatment for people with chronic heart failure

An experimental drug recently concluded a successful third-phase clinical trial and could potentially offer a new treatment for about 300,000 Canadians who have worsening chronic heart failure.

30 Mar 2020

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020

Fast-acting anti-malarial compound shows promise in first clinical trial

A fast-acting anti-malarial compound discovered at St. Jude Children's Research Hospital was well tolerated and showed promising anti-malarial effects in the first study in humans.

27 Mar 2020

Murdoch Children's Research Institute to roll-out clinical trial of BCG vaccine against COVID-19

Professor Kathryn North AC, Director of the Murdoch Children's Research Institute in Melbourne, Australia, has announced its infectious disease researchers are preparing to roll-out a multi-center randomized controlled clinical trial of the BCG vaccine against COVID-19.

26 Mar 2020

Clinical trial launched to investigate safety and efficacy of antiviral drug for COVID-19

Physician-scientists at four University of California Health medical centers -- UC San Diego Health, UC San Francisco, UC Irvine Health and UC Davis Health -- have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, an antiviral drug that has shown activity in animal models and human clinical trials of SARS-CoV, MERS-CoV, Ebola, Marburg and other viruses.

24 Mar 2020

First patients enrolled in new clinical trial to evaluate potential COVID-19 treatments

Researchers from the University of Oxford have launched a new clinical trial to test the effects of potential drug treatments for patients admitted to hospital with COVID-19. The first patients have now been recruited.

23 Mar 2020

Immunotherapy treatment shows promise for some patients with advanced rare cancers

A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers.

20 Mar 2020

Lopinavir and ritonavir drug combo tested in severe COVID-19

Researchers from China and the United Kingdom have collaborated to conduct a clinical trial looking at the efficacy of a combination of two anti-HIV drugs lopinavir and ritonavir to combat severe cases of COVID-19. Their study titled, “A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19,” was published in the latest issue of the New England Journal of Medicine (NEJM).

19 Mar 2020

Three-drug combination reduces all-cause mortality in COPD patients

Once-daily treatment of patients with chronic obstructive pulmonary disease (COPD) with an inhaler combining fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) reduced all-cause mortality by 42 percent, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

18 Mar 2020

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Preclinical trials indicate that a drug candidate called OxaliTex can stop the growth of cancer cells completely. OxaliTex appears to be more potent than many other common chemotherapy drugs, with less toxicity and less rapidly counteracted by mechanisms of drug resistance. The study was reported in the journal Proceedings of the National Academy of Sciences in March 2020.

16 Mar 2020

mRNA vaccine against novel coronavirus goes on a trial in Seattle

A clinical trial for a vaccine to protect against the novel coronavirus commenced this Monday in the U.S.. If successful, this could mean an end to the current global pandemic of COVID-19 infections, feel experts.

16 Mar 2020

Previous
1
...
82
83
84
85
86
87
88
...
1143
Next

Drug Trial News

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

Investigational drug vericiguat benefits patients with worsening heart failure

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

Taking ticagrelor alone better for patients with complex heart disease

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Experimental drug could offer new treatment for people with chronic heart failure

UC Davis launches two clinical trials to evaluate treatments for COVID-19

Fast-acting anti-malarial compound shows promise in first clinical trial

Murdoch Children's Research Institute to roll-out clinical trial of BCG vaccine against COVID-19

Clinical trial launched to investigate safety and efficacy of antiviral drug for COVID-19

First patients enrolled in new clinical trial to evaluate potential COVID-19 treatments

Immunotherapy treatment shows promise for some patients with advanced rare cancers

Lopinavir and ritonavir drug combo tested in severe COVID-19

Three-drug combination reduces all-cause mortality in COPD patients

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

mRNA vaccine against novel coronavirus goes on a trial in Seattle

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News